



MVP Health Care Medicaid Medical Policy

Herceptin (trastuzumab)- Medicaid

Type of Policy: Medical

Prior Approval Date: 07/01/2022

Approval Date: 11/01/2023

Effective Date: 01/01/2024

Related Policies: Experimental or Investigational Procedures Experimental or Investigational Procedures, Behavioral Health Services, Drugs and Treatments, Off-Label use of FDA Approved Drugs, and Clinical Trials Policy

Codes covered under the medical benefit

J9355 Injection, trastuzumab, excludes biosimilar, 10 mg

Administration Codes

96413 Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug

96415 Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure). Use 96415 in conjunction with 96413.

Overview

Herceptin (trastuzumab) is a recombinant DNA-derived humanized IgG1 kappa monoclonal antibody against the HER2 protein. It is indicated for the treatment of gastric cancer and breast cancer.

Indications/Criteria

On label use of Herceptin is covered under the member's medical benefit and is subject to retro-review only. Off label use is subject to prior authorization and must meet MVP's clinical coverage criteria for Experimental or Investigational Procedures Experimental or

Investigational Procedures, Behavioral Health Services, Drugs and Treatments, Off-Label use of FDA Approved Drugs, and Clinical Trials Policy.

References

1. Herceptin (trastuzumab) for injection, for intravenous use [prescribing information]. San Francisco, CA; Genentech, INC. November 2018.